Tumor size with polymer molecular

We have prepared several different molecular fractions of pyran, poly(acrylic acid-co-maleic acid) PAAMA, poly(maleic acid) PMA, and poly(acrylic acid-co-3,6-endoxo-l,2,3,6-tetrahydrophtha-lic acid) BCEP and evaluated their activity against Lewis lung carcinoma (Table I) andencephalomyocarditls (EMC) virus (Table II). Table I. Inhibition of Tumor Size with Polymer Molecular Weight... 

Polymer structure changes showed different effects in tumor size. All the polymers reduced the tumor growth by approximately T5% except for BCEP which only inhibited the growth by 30%. More importantly each polymer had a different effect on the increased life span (iLS) of the animal with pyran being the most effective (Uo% ILS) and BCEP the least (10% ILS). The molecular wei t did not have significant effect on the antitumor activity but did have a great effect on toxicity of the material which will be discussed later. 

Figure 2. A. Intratumor accumulation of various Cr-tagged proteins in solid tumor-bearing mice o, neocarzinostatin (NCS) (12 kDa) , SMANCS (16 kDa, but known to bind to albumin) , ovomucoid (29 kDa) , bovine serum albumin (69kOa) , mouse serum albumin (68 kDa) , mouse immunoglobulin G (160 kDa). Radiolabeled proteins were injected i.v. at time zero. Values are based on radioactivity (cf. Fig. 2). The tumor model in both A and B was solid sarcoma S-180 in mice. (From ref. 26, with permission). B. Relationship of drug distribution and molecular size to plasma concentration, AUC (area under the concentration curve), renal clearance, and intratumor uptake as expressed by percentage of injected dose. Putative polymer drugs are 1-Tyr-HPMA-copolymers of various molecular sizes given i.v. at 1.8 xlO cpm. The tumor model was sarcoma S-180 in mice. (From ref. 28 with permission).

---